Article Text

Download PDFPDF
The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer
  1. T. S. Barlow*,
  2. M. Przybylski,
  3. J. M. Schilder*,
  4. D. H. Moore* and
  5. K. Y. Look*
  1. *Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana
  2. Bowen Research Center, Department of Family Practice, Indiana University School of Medicine, Indianapolis, Indiana
  1. Address correspondence and reprint requests to: Katherine Y. Look, MD, Department of Obstetrics and Gynecology, Indiana University School of Medicine, 535 Barnhill Drive Room 434, Indianapolis, IN 46202. Email: klook{at}iupui.edu

Abstract

The objective of this study was to evaluate the ability of a preoperative serum CA125 to predict whether optimal debulking (OD) could be achieved for patients with stage III and IV epithelial ovarian cancer (EOC). The records of consecutive patients who underwent primary surgery for EOC at Indiana University Hospital between January 1997 and January 2003 were reviewed. Eligibility criteria included FIGO stage III/IV disease, surgery by gynecologic oncology faculty, preoperative CA125, and an operative note clearly defining volume of residual disease. The Medcalc software statistical package was used to generate a receiver-operating characteristic (ROC) curve. Two hundred and eighty-nine cases of stage III/IV EOC were identified, of which 164 met the eligibility criteria. Serum CA125 ≤400 was associated with OD ≥75% of the time. Conversely, OD was achieved in ≤40% of patients with CA125 ≥4500. The area under the ROC curve for CA125 was.670. The OD rate for those with and without ascites was 49% and 79%, respectively (P < 0.001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.686. We conclude that preoperative serum CA125 did not reliably predict OD in patients with stage III–IV EOC.

  • CA125
  • ovarian cancer
  • surgical debulking

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.